Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sichuan Kelun-Biotech Biopharmaceutical Co's quarterly market cap
increased
from Jun. 2025 (HK$76,298 Mil) to Dec. 2025 (HK$91,735 Mil) and
increased
from Dec. 2025 (HK$91,735 Mil) to Jun. 2026 (HK$101,716 Mil).
Sichuan Kelun-Biotech Biopharmaceutical Co's annual market cap
increased
from Dec. 2023 (HK$22,555 Mil) to Dec. 2024 (HK$38,181 Mil) and
increased
from Dec. 2024 (HK$38,181 Mil) to Dec. 2025 (HK$91,735 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sichuan Kelun-Biotech Biopharmaceutical Co's Enterprise Value for Today is HK$119,538 Mil.
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sichuan Kelun-Biotech Biopharmaceutical Co Market Cap Related Terms
Sichuan Kelun-Biotech Biopharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Kelun-Biotech Biopharmaceutical Co Market Cap Chart
Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Market Cap
0.00
0.00
22,555.17
38,181.02
91,735.37
Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
HKSE:06990 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Kelun-Biotech Biopharmaceutical Co Market Cap vs Biotechnology Industry
Sichuan Kelun-Biotech Biopharmaceutical Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a Market Cap of HK$125,010 Mil as of Aug. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. According to the industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #24 out of 1422 companies in the Biotechnology industry, placing it in the top 1.7%.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's Market Cap too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current Market Cap is HK$125,010 Mil. Based on the distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #24 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #24 out of 1422 companies for Market Cap. This places Sichuan Kelun-Biotech Biopharmaceutical Co in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 122.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.31, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median Market Cap is 122.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Kelun-Biotech Biopharmaceutical Co's current Market Cap is HK$125,010 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current Market Cap is HK$125,010 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current Market Cap is HK$125,010 Mil as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued.
The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91.
GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.
Key valuation signals for HKSE:06990:
Market Cap: HK$125,010 Mil
GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score
Get the complete analysis for HKSE:06990
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06990 has been successfully added to your 
